The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma

BMC Cancer

Research Article

Jie Huang¹  Xiaojing Li¹  Jieakesu Su¹  Yifan Xu¹  Haixing Wang¹  Yuan Shi¹  Yingyong Hou¹  Shaohua Lu¹  Haiying Zeng¹  Dongxian Jiang¹  Chen Xu¹  Lijie Tan² 

[1] Department of Pathology, Zhongshan Hospital, Fudan University, 200032, Shanghai, People’s Republic of China;Department of Thorax Surgery, Zhongshan Hospital, Fudan University, 200032, Shanghai, People’s Republic of China;

关键词: Esophageal squamous cell carcinoma;    Epidermal growth factor receptor;    Immunohistochemistry scoring system;    Fluorescence in situ hybridization;   

DOI  :  10.1186/s12885-015-1393-8

 received in 2015-02-05, accepted in 2015-04-29,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundIn view of the prominent role in cancer cell biology and alteration in substantial numbers of ESCC, defining EGFR molecular characteristics relevant to patient prognosis is of great importance. Therefore, we analyzed the protein expression and gene copy variation of the epithelial growth factor receptor (EGFR) in Chinese esophageal squamous cell carcinoma (ESCC) and explored the possible associations with various features of the tumors and survival of the patients.MethodsSections were made from tissue microarray composed of 96 ESCC, and examined for EGFR expression by means of immunohistochemistry (IHC) and for EGFR gene amplification by means of fluorescence in situ hybridization (FISH). The results of IHC were evaluated with six different reported scoring systems. Correlation with clinical features and survival was evaluated using chi-square test and Kaplan–Meier analysis.ResultsEGFR overexpression according to scoring system 1 significantly correlated with advanced lymph node involvement (P = 0.046), patient disease specific free survival (DFS) (P = 0.006) and overall survival (OS) (P = 0.007). No such association was observed using other 5 scoring systems (P > 0.05 ). EGFR amplification was associated with lymph node metastasis (P = 0.028), but not correlated with DFS and OS until 20 months.ConclusionsEGFR IHC overexpression evaluated by scoring system 1 might be suitable to be used in predicting patients survival in ESCC. EGFR gene amplification showed delayed prognostic information after 20 months.

【 授权许可】

Unknown   
© Jiang et al.; licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.